A
Alcista
Alcista · 25%VTRS
$10.07
Precio del escenario
$18.655
+0.446 (+2.39%)Al cierre
Loading chart…
- Máximo
- 18.665
- Apertura
- 18.200
- Precio medio ponderado por volumen
- 18.49
- Volumen
- 9.42M
- Capitalización
- 12.48B
- Mínimo
- 18.150
- Importe
- 174.22M
- EV/EBITDA, TTM
- 7.18
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases.
Análisis de IA of Viatris Inc (VTRS)
ComprarViatris Inc is a good buy right now due to its recent FDA approval for RYZUMVI, which is expected to drive revenue growth, and a strong forward P/E ratio of 6.38, suggesting the stock is undervalued. Additionally, the stock has shown a year-to-date change of +49.72%, indicating strong momentum. However, the main risk is the significant insider selling, which has increased by 247.32% over the last quarter, suggesting potential concerns about future performance.
Métricas de valoración
El PER previsto actual de Viatris Inc (VTRS) es 6.38, frente a su media de 5 años de 4.18.
Escenarios de precio de Alphio AI para VTRS
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con VTRS en cartera
Cronología de eventos
Noticias
9.010-16PRnewswireViatris Receives FDA Approval for RYZUMVI to Treat Presbyopia
8.510-16stocktwitsOpus Receives FDA Approval for New Eye Drop
8.510-12stocktwitsViatris to Acquire Pacira BioSciences for $1.65 Billion
7.510-12stocktwitsBiotech Firms Set to Release Key Data This Week
8.510-10stocktwitsViatris Acquires Pacira BioSciences for $1.65 Billion
Preguntas frecuentes sobre VTRS, respondidas por Alphio AI
Viatris Inc. is a global healthcare company. The Company markets branded and generic drugs, including complex drugs. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. Its Developed Markets segment comprises its operations primarily in North America and Europe. The Company's Greater China segment includes its operations in mainland China, Taiwan and Hong Kong. The Company's JANZ segment consists of its operations in Japan, Australia and New Zealand. Its Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies including in Asia, Africa, Eastern Europe, Latin America and the Middle East as well as the Company's ARV franchise. It produces medicines for patients across a broad range of major therapeutic areas. From cardiovascular health to oncology, it offers treatment options across more than 10 major therapeutic areas covering a variety of noncommunicable and infectious diseases. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Viatris Inc is a good buy right now due to its recent FDA approval for RYZUMVI, which is expected to drive revenue growth, and a strong forward P/E ratio of 6.38, suggesting the stock is undervalued. Additionally, the stock has shown a year-to-date change of +49.72%, indicating strong momentum. However, the main risk is the significant insider selling, which has increased by 247.32% over the last quarter, suggesting potential concerns about future performance.
Comunidad
Más ↗
5 Trade Ideas for Monday: Apple, Intercontinental Exchange, Cheniere Energy, Viatris and Zoetis $AAPL $ICE $LNG $VTRS $ZTS
Mostrar másEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.